Abstract:Objective To investigate the effect and safety of Agomelatine in the treatment of depression.Methods A total of 197 patients with depression in Ganzhou People′s Hospital from June 2017 to December 2018 were selected as the research objects, according to the double-blind random method, they were divided into the observation group (101 cases, 3 cases of shedding and the rest 98 cases) and the control group (96 cases, 2 cases of shedding and the rest 94 cases).The control group was treated with Paroxetine, and the observation group was treated with Agomelatine.The clinical effective rate, Hamilton depression scale (HAMD) score and adverse reactions were compared between the two groups.Results The clinical effective rate of the observation group was 91.84%, compared with 93.62% of the control group, the difference was not statistically significant (P>0.05).The HAMD scores of the two groups at the end of the 2nd and 4th weeks were lower than those before treatment, and the HAMD scores of the observation group at the end of the 2nd and 4th weeks were lower than those of the control group, the differences were statistically significant (P<0.05).There were no significant differences in the incidence of sleep disorders, upright collapse, physical fatigue, headache, palpitation, tremor, dysuria, sweating, dry mouth, constipation, sleepiness and other adverse reactions between the two groups(P>0.05).The incidence of sexual dysfunction in the observation group was lower than that in the control group, the difference was statistically significant (P<0.05).Conclusion Both Agomelatine and Paroxetine can safely and effectively improve the symptoms of patients with depression, and the clinical efficacy is roughly the same, but Agomelatine has little effect on sexual function.
杜莉辉; 黄金荣; 邹称林; 徐晨雯. 阿戈美拉汀治疗抑郁症的临床研究[J]. 中国当代医药, 2021, 28(10): 106-108转116.
DU Li-hui ;HUANG Jin-rong; ZOU Cheng-lin; XU Chen-wen. Clinical research of Agomelatin in the treatment of depression. 中国当代医药, 2021, 28(10): 106-108转116.